The Journal of Immunology, Vol 157, Issue 2 582-588, Copyright © 1996 by American Association of Immunologists

ARTICLES

The role of the B7-1a molecule, an alternatively spliced form of murine B7-1 (CD80), on T cell activation

M Inobe, N Aoki, PS Linsley, JA Ledbetter, R Abe, M Murakami and T Uede
Section of Immunopathogenesis, Institute of Immunological Science, Hokkaido University, Sapporo, Japan.

B7 molecules (CD80 (B7-1) and CD86 (B7-2/B70)) on APCs provide costimulatory signals for T cell proliferation. We previously described the presence of an alternatively spliced form of murine CD80 (previously termed MB7-2 and renamed as B7-1a) that completely lacks the second Ig-like domain coded by exon 3 in activated murine B cells. in this study, we first examined whether B7-1a mRNA can be detected in vivo by RNase protection assay. The expression of B7-1a mRNA was only detected in lymphoid organs although the level of expression was lesser than that of CD80 mRNA. However, we demonstrated that the expression of B7-1a mRNA like CD80 mRNA was considerably augmented in spleen cells treated with either LPS in vitro or OVA/CFA conjugate in vivo. We next determined the functional activity of B7-1a using Chinese hamster ovary (CHO) cells transfected by B7 genes. When resting T cells were cocultured with CHO cells expressing B7-1a molecules in the presence of PMA/ionomycin, T cell proliferation was not detected, while CHO cells either expressing CD80 or CD86 could promote the proliferation of resting T cells. in contrast to resting T cells, CHO cells expressing B7-1a could support the proliferation of activated T cells. Thus, costimulatory activity of B7-1a molecules was dependent upon the activation stage of T cells. Therefore the IgV-like region of CD80 contains a critical region for functional interaction with its ligands and can transduce a costimulatory signal for T cell proliferation.

This article has been cited by other articles:

				E. K. Kapsogeorgou, H. M. Moutsopoulos, and M. N. Manoussakis A Novel B7-2 (CD86) Splice Variant with a Putative Negative Regulatory Role J. Immunol., March 15, 2008; 180(6): 3815 - 3823. [Abstract] [Full Text] [PDF]

				I. Tirapu, E. Huarte, C. Guiducci, A. Arina, M. Zaratiegui, O. Murillo, A. Gonzalez, C. Berasain, P. Berraondo, P. Fortes, et al. Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma Cancer Res., February 15, 2006; 66(4): 2442 - 2450. [Abstract] [Full Text] [PDF]

				D. Dudziak, F. Nimmerjahn, G. W. Bornkamm, and G. Laux Alternative Splicing Generates Putative Soluble CD83 Proteins That Inhibit T Cell Proliferation J. Immunol., June 1, 2005; 174(11): 6672 - 6676. [Abstract] [Full Text] [PDF]

				M. G. Agadjanyan, M. A. Chattergoon, M. J. Holterman, B. Monzavi-Karbassi, J. J. Kim, T. Dentchev, D. Wilson, V. Ayyavoo, L. J. Montaner, T. Kieber-Emmons, et al. Costimulatory Molecule Immune Enhancement in a Plasmid Vaccine Model Is Regulated in Part Through the Ig Constant-Like Domain of CD80/86 J. Immunol., October 15, 2003; 171(8): 4311 - 4319. [Abstract] [Full Text] [PDF]

				C. Vasu, A. Wang, S. R. Gorla, S. Kaithamana, B. S. Prabhakar, and M. J. Holterman CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties Int. Immunol., February 1, 2003; 15(2): 167 - 175. [Abstract] [Full Text] [PDF]

				S. J. Faas, M. A. Giannoni, A. P. Mickle, C. L. Kiesecker, D. J. Reed, D. Wu, W. L. Fodor, J. P. Mueller, L. A. Matis, and R. P. Rother Primary Structure and Functional Characterization of a Soluble, Alternatively Spliced Form of B7-1 J. Immunol., June 15, 2000; 164(12): 6340 - 6348. [Abstract] [Full Text] [PDF]

				A. A. ROSSINI, D. L. GREINER, and J. P. MORDES Induction of Immunologic Tolerance for Transplantation Physiol Rev, January 1, 1999; 79(1): 99 - 141. [Abstract] [Full Text] [PDF]